REG - Haleon PLC - Environmental & Social Sustainability Committee

HALEONAnnouncement

09/03/2023 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230309:nRSI4853Sa&default-theme=true

RNS Number : 4853S  Haleon PLC  09 March 2023

 

 

Haleon plc: Establishment of Environmental and Social Sustainability Committee

 

9 March 2023: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that
with effect from today, the Board has established the Environmental and Social
Sustainability Committee (the "Committee"). The role of the Committee is to
provide oversight and effective governance over progress with the
environmental and social sustainability agenda of the Company and the external
governance and regulatory requirements relevant to these areas.

 

The members of the Committee, all of whom are independent Non-Executive
Directors of the Company, are Marie-Anne Aymerich (Chair of the Committee),
Tracy Clarke and Dame Vivienne Cox.

 

Further information about the governance arrangements of the Company and the
Terms of Reference of the Committee are available at www.haleon.com
(http://www.haleon.com) .

 

This announcement is made in accordance with Listing Rule 9.6.11.

 

 

Amanda Mellor

Company Secretary

 

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZGGFDLGGFZM